Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis | Zendy

Renata Rodrigues da Cunha Colombo Bonadio | Zendy; Renata Gondim Meira Velame de Azevedo | Zendy; Guilherme Harada | Zendy; Samantha Cabral Severino da Costa | Zendy; Vanessa Costa Miranda | Zendy; Daniela Freitas | Zendy; Elias Abdo Filho | Zendy; Patrícia Alves Ferreira | Zendy; Flavia Gabrielli | Zendy; Maria Del Pilar Estevez Diz | Zendy

Open Access

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Author(s) -

Renata Rodrigues da Cunha Colombo Bonadio,

Renata Gondim Meira Velame de Azevedo,

Guilherme Harada,

Samantha Cabral Severino da Costa,

Vanessa Costa Miranda,

Daniela Freitas,

Elias Abdo Filho,

Patrícia Alves Ferreira,

Flavia Gabrielli,

Maria Del Pilar Estevez Diz

Publication year - 2018

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.17.00146

Subject(s) - medicine , carboplatin , endometrial cancer , radiation therapy , oncology , chemotherapy , lymphadenectomy , carcinosarcoma , cancer , paclitaxel , carcinoma , cisplatin

The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research